Vontobel Holding Ltd. lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 84.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 347,498 shares of the medical instruments supplier's stock after selling 1,934,978 shares during the period. Vontobel Holding Ltd. owned 0.12% of Becton, Dickinson and Company worth $59,857,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in BDX. Vanguard Group Inc. boosted its holdings in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after acquiring an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Becton, Dickinson and Company by 3.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock worth $2,880,510,000 after acquiring an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after acquiring an additional 667,957 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Becton, Dickinson and Company by 7.6% in the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock worth $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Becton, Dickinson and Company by 1.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock worth $707,872,000 after acquiring an additional 37,733 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have recently commented on BDX. Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a report on Wednesday. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Royal Bank Of Canada assumed coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They set a "sector perform" rating and a $211.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and an average target price of $205.40.
View Our Latest Analysis on Becton, Dickinson and Company
Becton, Dickinson and Company Trading Up 0.7%
NYSE BDX opened at $193.85 on Thursday. The stock's 50-day simple moving average is $189.65 and its two-hundred day simple moving average is $186.88. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $55.56 billion, a price-to-earnings ratio of 34.87, a PEG ratio of 1.50 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter last year, the business posted $3.50 earnings per share. The company's revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.
Insider Activity
In other news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,023 shares of company stock worth $562,036. Company insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
